Navigation Links
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
Date:10/18/2011

implifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint®, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and costly methods.

In addition to the Symphony™ suite of tests, Agendia has a rich pipeline of genomic products in development based on its world-class genomic platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Amsterdam, the Netherlands, and Irvine, California, United States.

For more information about Agendia please visit:  http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Agendia Successfully Completes Bi-Annual FDA Inspection
2. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
3. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
4. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
5. Agendia Raises US $23 Million in Series E Financing
6. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
7. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
8. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
9. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
10. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
11. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014  United Therapeutics Corporation (NASDAQ: ... well as changes to Martine Rothblatt , Ph.D,s ... United Therapeutics announced the promotion of ... Officer and David Zaccardelli , Pharm.D. to Executive ... these promotions, Dr. Rothblatt,s title will change from Chairman ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... 2011 Reportlinker.com announces that a new market research ... The Future of In Vitro and In ... The term in-vitro/in-vivo diagnostics (IV2D) ... and pathology (imaging), as well as new software ...
... YORK, Jan. 25, 2011 Reportlinker.com announces ... available in its catalogue: ... Implications of Emerging Reimbursement, Technological and Market ... http://www.reportlinker.com/p0365288/Future-US-In-Vitro-Diagnostics-Market-Strategic-Implications-of-Emerging-Reimbursement-Technological-and-Market-Trends-through-2018.html How will ...
... 23, 2011 An interdisciplinary team from Columbia University ... together with researchers from the University,s departments of Physics ... single-molecule interactions on very short time scales using nanoscale ... 23 in Nature Nanotechnology , they show how, ...
Cached Biology Technology:Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2Columbia University researchers use nanoscale transistors to study single-molecule interactions 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Amsterdam, 16 March, 2011 A recent special edition ... Elsevier, on behalf of the British Mycological Society, features a ... collection of fungal cell biology movies ever published. The movies ... Exeter, UK, who is a renowned researcher in the field ...
... analyze the complex ingredients in the new genre of ... for cigarettes in places where smoking is banned have ... The report appears in ACS,s Journal of Agricultural ... colleagues point out that the first dissolvable tobacco products ...
... Trends in Plant Science , provides an overview ... for ecologists, physiologists and molecular biologists, since it covers ... change. The results show that plants in ... to a changing environment without requiring any evolutionary changes, ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Plasticity of plants helps them adapt to climate change 2